On Monday, October 15 2018, CMS released a proposed rule related to drug price transparency.
On Monday, October 15 2018, the Centers for Medicare and Medicaid Services (CMS) released a proposed rule related to drug price transparency.
The proposed rule would require manufacturers to include the list price (defined as the Wholesale Acquisition Cost) in direct-to-consumer (DTC) television advertisements for prescription drug and biological products for which reimbursement is made through Medicare or Medicaid. This proposal is part of the broader American Patients First blueprint released earlier this year by the Administration.
There is a 60-day public comment period.
